the aid library

LIST OPTIONS

Filter

10954

Download (528)

View PDF (358)

Pandemic Influenza Risk Management. Chinese Version. 流感大流行风险管理
recommended

World Health Organization WHO (2017) C_WHO

Download (720)

View PDF (1093)

Validation of elimination of trachoma as a public health problem

World Health Organization WHO (2016) C_WHO

These standard operating procedures are intended to be used when a Member State wishes to request validation of national elimination of trachoma as a public health problem following implementation of the SAFE strategy,1 which comprises: surgery for trachomatous trichiasis, antibiotics to clear infec... more

External Link

Self-Help Booklet for Men facing crisis and displacement (Arabic)

International Organization for Migration IOM (2014) C2

The booklet “Self-Help for Men facing crisis and displacement”, is a new IOM publication developed as an activity of our psychosocial support program in the Syrian Arab Republic and Lebanon, in Arabic and English

Download (314)

View PDF (480)

Regional Situation Report for Syria Crisis Issue No. 92 April 1-30 2020

United Nations Population Fund UNFPA (2020) C1

External Link

Non communicable diseases kit 2016 (NCDK)

WHO Regional Office for the Eastern Mediterranean (2017) C_WHO

WHO has developed a new health kit to support treatment for chronic disease patients in emergency settings. The prevalence of NCDs is increasing worldwide, including in emergency/crisis-prone areas. Yet current humanitarian response has not accounted for this emerging burden. The NCD kit attends to ... more

Download (457)

View PDF (704)

Evaluation of the Free Diagnostics Scheme in Andhra Pradesh

Ministry of Health & Family Welfare, India World Health Organization WHO, India (2018) C_WHO

Download (1165)

View PDF (2035)

Virus del Ébola

International SOS (2014)

Download (923)

View PDF (1613)

Integrating palliative care and symptom relief into paediatrics: a WHO guide for health-care planners, implementers and managers

World Health Organization WHO (2018) C_WHO

People younger than 20 years comprise 35% of the global population and 40% of the global population of least-developed nations. The number of children - neonates, infants, children, and adolescents up to 19 years of age - who need pediatric palliative care (PPC) each year may be as high as 21 millio... more

Download (753)

View PDF (1043)

Mein Körper gehört mir. Kurdish Version

Pro Familia (2017) CC

Das Buch wurde ins Kurdische übersetzt und mit freundlicher Genehmigung von PRO FAMILIA Darmstadt und dem Loewe Verlag in der Kindertherapie in Kurdistan eingesetzt.

Download (860)

View PDF (1706)

Integrating palliative care and symptom relief into primary health care : WHO guide for planners, implementers and managers

World Health Organization WHO (2018) C_WHO

Inequality of access to palliative care and symptom relief is one of the greatest disparities in global health care (1). Currently, there is avoidable suffering on a massive scale due to lack of access to palliative care and symptom relief in low- and middle-income countries (LMICs) (1). Yet basic p... more

Download (1302)

View PDF (2200)

Ƙwayar cutar Ebola Toolbox Talk

International SOS (2014)

Download (473)

View PDF (370)

Impact of coronavirus disease on different manifestations of sale and sexual exploitation of children

M. F. Singhateh United Nations (2021) CC

In the present report, the Special Rapporteur on the sale and sexual exploitation of children, including child prostitution, child pornography and other child sexual abuse material, Mama Fatima Singhateh, focuses on the impact of the coronavirus disease (COVID-19) p... more

Download (595)

View PDF (788)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (5304)

View PDF (3774)

Standard Treatment Guidelines. Nigeria

Federal Ministry of Health Nigeria , World Health Organisation (WHO) (2008) C_WHO

Download (2571)

View PDF (1674)

Clinic Supervisor Manual

Management Sciences for Health; USAID (2006) C1

This Clinic Supervisor’s Manual is helpful for focusing managers on the key elements of integrated primary health care as they simultaneously integrate new interventions for HIV/AIDS, tuberculosis, and malaria. This tool contains 12 sections. Section 1 explains how to use the manual. Section 2 hel... more

Download (968)

View PDF (1634)

SENSIBILIZAÇÃO SOBRE O ÉBOLA

International SOS (2014)

Download (1037)

View PDF (2188)

Ebola Awareness Talk

International SOS (2014)

External Link

Strategic Plan of Action and Budget 2016 – 2025 for Elimination of Onchocerciasis in Africa

World Health Organization WHO African Prgramme for Onchocerciasis Control (2012) C_WHO

The Strategic Plan of Action and Budget 2016-2025 for the elimination of onchocerciasisin countries was prepared based on the above dlrective for the consideration of IAF 18.The vision of the plan of action is to eliminate onchocerciasis in 80 percent of Africancountries. Implementation of the plan ... more

Download (476)

View PDF (708)

World Drug Report 2019 Booklet 3 Drug market trends of Cannabis and Opioids

United Nations Office on Drug and Crime UNODC (2022) C2

This third booklet of the World Drug Report 2022 has a dual focus: opioids and cannabis. The first chapter of the booklet provides an overview of opioids as a group of substances and their patterns of non-medical use at the global level. It also reviews the latest trends in the global supply of opi... more

Download (436)

View PDF (506)

World Drug Report 2019 Booklet 1 Executive summary / Policy implications

United Nations Office on Drug and Crime UNODOC (2022) C1

The World Drug Report 2022 is aimed not only at fostering greater international cooperation to counter the impact of the world drug problem on health, governance and security, but also, with its special insights, at assisting Member States in anticipating and address-ing threats from drug markets an... more

Pandemic Influenza Risk Management. Chinese Version. 流感大流行风险管理 recommended

Pandemic Influenza Risk Management. Chinese Version. 流感大流行风险管理
recommended